Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency

https://doi.org/10.1038/ncb3596 28th August 2017

Article highlights & insights

Apoptosis represents a key anti-cancer therapeutic effector mechanism. During apoptosis, mitochondrial outer membrane permeabilization (MOMP) typically kills cells even in the absence of caspase activity. Caspase activity can also have a variety of unwanted consequences that include DNA damage. We therefore investigated whether MOMP-induced caspase-independent cell death (CICD) might be a better way to kill cancer cells. We find that cells undergoing CICD display potent pro-inflammatory effects relative to apoptosis. Underlying this, MOMP was found to stimulate NF-κB activity through the downregulation of inhibitor of apoptosis proteins. Strikingly, engagement of CICD displays potent anti-tumorigenic effects, often promoting complete tumour regression in a manner dependent on intact immunity. Our data demonstrate that by activating NF-κB, MOMP can exert additional signalling functions besides triggering cell death. Moreover, they support a rationale for engaging caspase-independent cell death in cell-killing anti-cancer therapies.

Institute Authors

Group leader

Research topics & keywords

Meet the Research Team

Pengbo Wang
Pengbo Wang

Senior Scientific Officer

Alexander Vdovin Postdoctoral Fellow
Alexander Vdovin

Postdoctoral Scientist

Flurina Bohi
Flurina Bohi

Postdoctoral Scientist

Laura Cogrossi
Laura Cogrossi

Postdoctoral Scientist

Daniel Su
Daniel Su

Postdoctoral Scientist

Swara Patel
Swara Patel

PhD Student

Portrait image of Emma West from Cancer Research UK MI
Emma West

PhD Student

All publications

Filter by group
Filter by group leader
Filter by research topic
Filter by year
Search publications

Annual Report 2025

2025 Annual Report

11 November 2026

https://www.sciencedirect.com/science/article/pii/S2666634026003387?via%3Dihub

Bacteria inside kidney tumors associate with myeloid inflammation and disease progression: A TRACERx Renal study

23 October 2026

Institute Authors (1)

Samra Turajlić

Research Group

Cancer Dynamics

array(1) { [0]=> int(8377) }

https://royalsocietypublishing.org/rsob/article/16/8/260089/482862/CDK1-Cyclin-B-mediated-phosphorylation-of-PP2A-B56

CDK1-Cyclin B mediated phosphorylation of PP2A-B56 on B56Par1.T73T75 controls mitotic entry timing and Schizosaccharomyces pombe cell size

19 August 2026

Institute Authors (3)

Lenka Halova, Duncan Smith, Iain Hagan

Labs & Facilities

Biological Mass Spectrometry

array(1) { [0]=> int(3758) }

Research Group

Cell Division

array(1) { [0]=> int(1855) }

https://www.cell.com/immunity/fulltext/S1074-7613(26)00278-5

CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity

4 August 2026

Institute Authors (10)

Erin Richardson, Shih-Chieh Chiang, Massimo Russo, Charles Earnshaw, Anna Pidoux, Poppy Dunn, Sudhakar Sahoo, Antonia Banyard, Natalia Moncaut, Santiago Zelenay

Labs & Facilities

BRU Experimental Team, Computational Biology Support, Genome Editing and Mouse Models, Mass and Flow Cytometry, Transgenic Breeding Team

array(5) { [0]=> int(3679) [1]=> int(3839) [2]=> int(2947) [3]=> int(2104) [4]=> int(9553) }

Research Group

Cancer Inflammation and Immunity

array(1) { [0]=> int(1957) }

https://www.cell.com/cell/fulltext/S0092-8674(26)00522-2

Plasma signals of lung tumor promotion for molecular cancer prevention

25 June 2026

Institute Authors (1)

William Hill

Research Group

Cancer Origins

array(1) { [0]=> int(7954) }

https://link.springer.com/article/10.1038/s44319-026-00809-1

PKMYT1 has an important role in the timing and fidelity of chromosome segregation

5 June 2026

Institute Authors (6)

Asma Belbelazi, Charlie Greenaway-Wells, Zoe Edwards, Wendy Trotter, Keren Dawson, Iain Hagan

Research Group

Cell Division

array(1) { [0]=> int(1855) }
Four individuals pose together in a laboratory. They're wearing lab coats each with a Cancer Research UK logo.
An immunofluorescence microscopy image of kidney tissue showing different tissue structures stained in red, blue, and green The blue colour (DAPI) is widespread, indicating the location of cell nuclei throughout the sample. The green colour (LTL) highlights specific regions, indicating the presence of proximal tubule cells. The red colour (NPHS1) is also distinct in certain areas, showing the presence of podocytes in the glomeruli. The overlapping colours in some regions suggest the complex structure and the close association of these different cell types within the kidney.

Latest from CRUK MI

New major support for our lung cancer prevention research

ScottishPower has committed £690,000 to co-fund our Cancer Origins research group with the University of Manchester, enabling investigations into what causes lung cancer to emerge and how we can prevent it.

New publication: Bacteria inside kidney tumors associate with myeloid inflammation and disease progression – A TRACERx Renal study

Research explores the role of intratumour bacteria in disease progression

Read our latest Scientific Report

The latest Scientific Report highlights an incredible year of growth for the Institute and many research successes. We welcomed a new Director, Samra Turajlić to the Institute, and saw the establishment of three new independent research groups.

New major support for our lung cancer prevention research
New publication: Bacteria inside kidney tumors associate with myeloid inflammation and disease progression – A TRACERx Renal study
Read our latest Scientific Report

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Institute life in Manchester

We strive to make our community a welcoming, caring and enthusiastic one, fuelling ambition with opportunities for training and mentoring to help us all achieve our personal and professional goals.

“We are so pleased to have received the funding to enable us to test our hypothesis in the lab. If we can create a new medicine that can precisely target a specific type of cell within the tumour, and restore anti-cancer immune responses, this will be a game-changer for oesophageal cancer patients “

Sara Valpione

Former Institute Clinical Fellow and now Clinician in Residence within the CRUK National Biomarker Centre

“My charity bake sales – known as “David’s Great British Bake Off” – are always a hit, home baked products taste so much better than shop bought and are greatly appreciated by staff!”

David Jenkins

Purchasing Officer

“We’ve seen some remarkable responses, with an improvement for some patients within days. This is an early phase trial so there’s a lot more work to do. But the data we have so far is very encouraging and could help many thousands of people in the future”

Tim Somervaille

Senior Group Leader

“It is a pleasure to introduce my team who work to deliver our research goals. We work in a friendly and collaborative environment, supporting each other’s projects.  “

Amaya Virós

CRUK Advanced Clinician Scientist Fellow